The overall incidence of PEP was @ % ( @/@ ) and no significant differences were observed between ulinastatin and nafamostat groups in terms of the incidences of PEP ( @ % and @ % , P = @ ) , hyperamylasemia , hyperlipasemia , and abdominal pain , although these were significantly lower than those of the control group ( P < @ ) .